Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial
Jean‐Michel Molina(Inserm), Juergen Rockstroh, Nina Weis, George J. Hanna(Merck & Co., Inc., Rahway, NJ, USA (United States)), Alex Lund Laursen, Alexander Zoufaly, Anthony Rodgers(New South Wales Department of Health), Christine Katlama(Inserm), Sushma Kumar(Merck & Co., Inc., Rahway, NJ, USA (United States)), Peter Sklar(Merck & Co., Inc., Rahway, NJ, USA (United States)), Norma Porteiro, Johan Lombaard, Xia Xu(Merck & Co., Inc., Rahway, NJ, USA (United States)), Carolina Eugenia Chahin, Alejandro Afani, Carey Hwang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Richard James Moore, Mark Bloch, Robert Finlayson, Lisa Lupinacci(Merck & Co., Inc., Rahway, NJ, USA (United States)), Pedro Cahn(Fundación Huésped), Gustavo Lopardo, Yazdan Yazdanpanah, Graham Smith, Sylvia Hartl, Armin Rieger, Maria Isabel Enriqueta Campos Barker, Carlos Enrique Tene Pérez, James McMahon, Ming‐Tain Lai(Efficient Pharma Management (Taiwan)), Edwin DeJesus(Orlando Immunology Center), David Alfred Baker, Jan Gerstoft, Francois Raffi, Philippe Morlat, Anita Rachlis(University of Toronto), Brian Conway, Norman Roth, Robert Zangerle, Fiona Smaill, Marcelo Martins, Laurent Cotte(San Francisco General Hospital), Bach‐Yen Nguyen(Merck & Co., Inc., Rahway, NJ, USA (United States)), Pierre-Marie Girard, Paul E. Sax(Brigham and Women's Hospital), Kathleen Squires(Thomas Jefferson University), Sharon Walmsley
Cited by 145
Related Papers
Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
|New England Journal of Medicine|2008|7.4k
Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis
|The Lancet|2015|3.7k
Selected major risk factors and global and regional burden of disease
|The Lancet|2002|3.6k
Comparative quantification of health risks : global and regional burden of disease attributable to selected major risk factors
|Unknown|2004|3.3k
Antiretroviral Treatment of Adult HIV Infection
|JAMA|2012|2.5k